At this symposium, industry leading scientists will demonstrate how High Throughput SPR has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection.
You will learn how throughput advances in label-free SPR are facilitating the analysis of large panels of antibodies by providing a deep insight into the epitope landscape of antibody campaigns, informing decision-making in the drug discovery process.
8:30 am – 9:00 am | Registration & Coffee | ||
9:00 am – 9:45 am |
|
Yasmina Abdiche, PhD
Chief Scientific Officer
Carterra
|
Overview of the Day: Why High Throughput mAb Characterization? |
9:45 am – 10:30 am | Jack Bevers III Senior Scientific Researcher
Genentech
|
Implementing High Throughput SPR into Antibody Discovery and Engineering Workflows |
|
Abstract: Technological advancements and improvements to the antibody workflows within the Antibody Discovery group have led to generation of hundreds to thousands of clones for an individual campaign. Characterizing these to identify clones of interest has thus created bottlenecks in the discovery workflow process. Implementing Carterra's technology into the discovery workflow has enabled HTP binning and binding kinetics with small amounts of material resulting in faster identification of potential therapeutic antibody candidates. |
|||
10:30 am – 11:00 am |
Networking Break |
||
11:00 am – 11:45 am | Kathryn Ching, PhD Senior Scientist
Ligand Pharmaceuticals
|
Use of High Throughput SPR to Validate |
|
Abstract: The generation of antibodies to therapeutic targets with high conservation between rodents and humans is a challenge. Because of their increased evolutionary distance from humans compared to rodents, chickens are an ideal species to circumvent this challenge. We have developed several lines of transgenic chickens in which both VL and VH genes have been replaced with fully human V regions. Using our GEM Technology, we are able to retrieve fully human monoclonal antibodies which retain the native VL and VH pairing that has undergone affinity maturation in vivo. With each new line of OmniChickens, we employ high throughput SPR to assess and validate antibodies against a model antigen. Here we present SPR kinetic and epitope binning results comparing our V-kappa and V-lambda OmniChickens paired with either a pre-rearranged or rearranging heavy chain. While the different antibody cohorts demonstrate similar kinetics, with many binding affinities in the pM range, epitope binning results suggest certain biases toward specific epitopes of the model antigen depending on which VL is present. In addition, the use of high throughput SPR allowed us to tease out more subtle relationships between antibodies in a given epitope bin. The analysis of large cohorts of antibodies in a single experiment against a model antigen in the different OmniChicken lines is an important metric in assessing the immune repertoire of our birds. |
|||
11:45 am – 12:30 pm | Daniel Bedinger, PhD Senior Applications Scientist
Carterra
|
Carterra LSA Technology Overview | |
12:30 pm – 1:30 pm |
Lunch |
||
1:30 pm – 2:15 pm | Jacob Glanville, PhD Chief Scientific Officer
Distributed Bio
|
How Computational Immunoengineering and High Throughput Kinetic Screening Can Realize the Dream of a One-Week Antibody Discovery Cycle |
|
2:15 pm – 3:00 pm | Raphael Levy, PhD Director, Antibody Engineering
LakePharma
|
Discovery and Characterization of Potent TIGIT-specific Antibodies Derived from Very Diverse Phage Display Libraries | |
Abstract: Antibody candidates targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains) were discovered via panning using LakePharma’s licensed state-of-the-art naïve Fab (XOMA) and in-house antigen specific immune libraries. Screening of these libraries was then performed using our liquid handling automation deck. We hereby present TIGIT-ligand inhibition data and kinetic characteristics of selected IgG-reformatted hits derived from phage panning, as well as details of antigen specificity attributes, such as epitope binning and polyspecificity assessments. |
|||
3:00 pm – 3:30 pm |
Round table discussion with the panel of speakers |
||
3:30 pm – 4:00 pm |
Networking Break |